Table 3.
Comparison of typical popPK parameter estimates in human with test set of clinical mAbs with linear PK.
| Human | Literature clinical mAbs |
|||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | Unit | Value (95% CI) | Bevacizumab | Infliximab AS | Infliximab UC | Pertuzumab | Rituximab | Trastuzumab |
| CL | mL/h/kg | 0.15 (0.14 – 0.16) | 0.12 | 0.16 | 0.24 | 0.13 | 0.15 | 0.13 |
| V1 | mL/kg | 46.31 (45.14 – 47.48) | 38.0 | 43.7 | 47.0 | 39.1 | 42.6 | 42.1 |
| Q | mL/h/kg | 0.27 (0.25 – 0.3) | 0.35 | 1.02 | 4.25 | 0.33 | 0.39 | 0.29 |
| V2 | mL/kg | 31.47 (28.63 – 34.31) | 39.4 | 42.0 | 59.0 | 30.9 | 52.0 | 68.4 |
CL: clearance from the central compartment, V1: volume of the central compartment, Q: inter-compartment distribution clearance, V2: volume of the peripheral compartment. 95% CI: 95% confidence interval calculated from the standard error. AS: ankylosing spondylitis; UC: ulcerative colitis